Trial Profile

A 24-week, randomised, double-blind, double-dummy parallel-group, multi-centre, active-controlled study to evaluate efficacy and safety of remogliflozin etabonate in subjects with type-2 diabetes mellitus

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 17 Mar 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Mar 2020 Results published in the Drugs
11 Jul 2019 According to a Glenmark Pharmaceuticals media release, the company has received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate in April 2019, after successful completion of Phase-3 clinical trials.
02 May 2019 According to an Avolynt media release, primary endpoint (Mean change in HbA1c levels from baseline) has been met.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com